ASCO In Brief
Executive Summary
Gleevec filing for first-line CML: Novartis plans to file an NDA for Gleevec (imatinib) for first-line use in chronic myeloid leukemia patients in late June or early July, company says. In a 1,106-patient open-label Phase III trial presented at a plenary session of the American Society of Clinical Oncology, patients receiving 400 mg daily of Gleevec achieved higher major and complete cytogenetic responses (84% and 69%) compared to those receiving interferon-alfa and cytarabine arabinoside (30% and 11.5%, respectively). Complete hematologic response rates were 96% for the Gleevec arm and 67% for the IFN/Ara-C arm. Gleevec is currently indicated for second-line use in CML...
You may also be interested in...
J&J Builds Oncology Presence: Zarnestra, Yondelis Slated For Filing In 2005
Johnson & Johnson expects to file NDAs for two oncologics - Zarnestra and Yondelis - as early as the first half of 2005, Pharmaceutical R&D President Harlan Weisman, MD, told analysts July 13
J&J Builds Oncology Presence: Zarnestra, Yondelis Slated For Filing In 2005
Johnson & Johnson expects to file NDAs for two oncologics - Zarnestra and Yondelis - as early as the first half of 2005, Pharmaceutical R&D President Harlan Weisman, MD, told analysts July 13
AstraZeneca Iressa Focus Is Sequential Therapy After INTACT Studies Fail
AstraZeneca is looking at Iressa monotherapy as an element of sequential chemotherapy regimens for solid tumors following the failure of the INTACT studies, VP-Medical Director of Oncology George Blackledge told an Aug. 19 conference call